Caredx, INC 8-K filings

CareDx reported a 52% year-over-year revenue increase to $132 million for Q2 2026, driven by strong Testing Services growth, and raised its full-year revenue and AEBITDA guidance.

CareDx, Inc. has finalized the sale of its Lab Products business to Eurobio Scientific for $171.7 million and acquired Naveris, Inc. for an initial $161.8 million, expanding its presence in specialty oncology.

CareDx's 2026 Annual Meeting saw stockholders approve an amendment to the 2024 Equity Incentive Plan, increasing available shares by 1.6 million.

CareDx, Inc. announced its definitive agreement to acquire Naveris, Inc. for $160 million in cash, with potential for an additional $100 million in milestone-based payments, expanding its precision medicine offerings into oncology.

CareDx, Inc. amends its prior 8-K filing to detail compensation adjustments for its newly appointed Chief Financial Officer, Keith Kennedy.

CareDx has entered into a definitive agreement to sell its Lab Products business to Eurobio Scientific for $170 million in cash to focus on core precision medicine testing.

CareDx, Inc. announced robust financial results for Q4 and full year 2025, including 14% full-year revenue growth, alongside a key executive appointment and 2026 financial guidance.

CareDx, Inc. announced its fourth quarter and full year 2025 financial results, reporting significant revenue growth and appointing Keith Kennedy as its new Chief Financial Officer and Chief Operating Officer.

CareDx announced preliminary unaudited financial results for Q4 and full year 2025, reporting significant revenue growth across all segments.

CareDx, Inc. has received preliminary court approval for a settlement in a shareholder derivative lawsuit, agreeing to significant corporate governance reforms.

CareDx, Inc. has amended its bylaws to implement a majority voting standard for director elections in uncontested races and a new director resignation policy.

CareDx, Inc. reported strong third-quarter 2025 financial results with total revenue increasing 21% year-over-year to $100.1 million and raised its full-year 2025 revenue and adjusted EBITDA guidance.

CareDx, Inc. announced the appointment of Suresh Gunasekaran, CEO and President of UCSF Health, as a Class II director to its Board, effective October 22, 2025.

CareDx, Inc. announced its second quarter 2025 financial results, reporting significant adjusted revenue growth and appointing a new Chief Financial Officer.

CareDx, Inc. announced that its stockholders approved an amendment to the 2024 Equity Incentive Plan, increasing the share reserve by 1.6 million shares, and re-elected two Class II directors at its 2025 Annual Meeting.

CareDx, Inc. announced the completion of its previous $50 million share repurchase program and the authorization of a new $50 million program, signaling confidence in its financial health and growth strategy.

CareDx announces an 18% year-over-year increase in first quarter revenue, reaching $84.7 million, driven by growth in testing services.

CareDx, Inc. has amended and restated its Change of Control and Severance Agreement with Chief Financial Officer Abhishek Jain, outlining the terms of severance benefits upon certain terminations of employment.

CareDx announces a 19% increase in full year 2024 revenue, reaching $334 million, and anticipates further growth in 2025.

CareDx reports preliminary Q4 2024 revenue expected to increase by 30% year-over-year, with full year 2024 revenue projected between $332 million and $333 million.

CareDx has updated its outside director compensation policy, modifying vesting schedules for equity awards and eliminating additional retainers for the board chairperson's prior role in the Office of the CEO.

CareDx reported strong third-quarter results, including a 23% year-over-year revenue increase and positive adjusted EBITDA, leading to an upward revision of their full-year financial outlook.

CareDx announced preliminary third-quarter 2024 results, highlighting a 23% year-over-year revenue increase and growth across all business lines.

CareDx announced that the Department of Justice has closed its investigation into the company, and the SEC has concluded its investigation without recommending enforcement action.

CareDx, Inc. has announced the departure of Alexander Johnson, President of Patient and Testing Services, and has entered into a separation and consulting agreement with him to ensure a smooth transition.

CareDx has appointed Keith Kennedy as Chief Operating Officer and Jessica Meng as Chief Commercial Officer to drive strategic growth initiatives.

CareDx announced a 31% year-over-year revenue increase for Q2 2024, alongside raised full-year revenue and adjusted EBITDA guidance.

CareDx, Inc. held its 2024 Annual Meeting of Stockholders, where they approved the 2024 Equity Incentive Plan and elected three Class I directors.

CareDx reported a 10% sequential revenue increase in the first quarter of 2024 and raised its full-year revenue guidance to $274-$282 million.

CareDx has appointed John W. Hanna as its new President and Chief Executive Officer, effective April 15, 2024, bringing extensive experience in molecular diagnostics and life sciences.